Moyamoya DiseaseSymptoms, Doctors, Treatments, Advances & More
Learn About Moyamoya Disease
Moyamoya disease is a disorder of blood vessels in the brain, specifically the internal carotid arteries and the arteries that branch from them. These vessels, which provide oxygen-rich blood to the brain, narrow over time. Narrowing of these vessels reduces blood flow in the brain. In an attempt to compensate, new networks of small, fragile blood vessels form. These networks, visualized by a particular test called an angiogram, resemble puffs of smoke, which is how the condition got its name: "moyamoya" is an expression meaning "something hazy like a puff of smoke" in Japanese.
The genetics of moyamoya disease are not well understood. Research suggests that the condition can be passed through families, and changes in one gene, RNF213, have been associated with the condition. Other genes that have not been identified may be involved in moyamoya disease. It is also likely that other factors (such as infection or inflammation) in combination with genetic factors play a role in the condition's development.
Moyamoya disease was first identified in Japan, where it is most prevalent, affecting about 5 in 100,000 individuals. The condition is also relatively common in other Asian populations. It is ten times less common in Europe. In the United States, Asian Americans are four times more commonly affected than whites. For unknown reasons, moyamoya disease occurs twice as often in females as in males.
Up to 15 percent of Japanese people with moyamoya disease have one or more family members with the condition, indicating that the condition can be passed through generations in families; however, the inheritance pattern is unknown. Research suggests that the condition follows an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder. However, some people who have a copy of the altered gene never develop the condition, which is a situation known as reduced penetrance.
Boston Pediatric Neurosurgical Foundation Inc
Edward Smith is a Pediatrics specialist and a Neurosurgery provider practicing medicine in Boston, Massachusetts. Dr. Smith is rated as an Elite provider by MediFind in the treatment of Moyamoya Disease. He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Moyamoya Disease, Vein of Galen Aneurysm, Wyburn-Mason Syndrome, and Arteriovenous Malformation. Dr. Smith is board certified in Neurological Surgery.
Northwell Health Neurosurgery & Spine
Amir Dehdashti is a Neurosurgery provider practicing medicine in Great Neck, New York. Dr. Dehdashti is rated as an Elite provider by MediFind in the treatment of Moyamoya Disease. He is also highly rated in 30 other conditions, according to our data. His clinical expertise encompasses Moyamoya Disease, Pituitary Tumor, Cerebral Arteriovenous Malformation, Cerebral Artery Bypass Surgery, and Extracranial-Intracranial Bypass Surgery.
Tower Health Medical Group Neurosurgery - West Reading
Ephraim Church is a Neurosurgery provider practicing medicine in West Reading, Pennsylvania. Dr. Church is rated as a Distinguished provider by MediFind in the treatment of Moyamoya Disease. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Moyamoya Disease, Brain Aneurysm, Arteriovenous Malformation, Cerebral Artery Bypass Surgery, and Extracranial-Intracranial Bypass Surgery. Dr. Church is board certified in American Board Of Neurological Surgery.
Summary: The purpose of this prospective randomized controlled trial is to compare the total consumption of remimazolam between two different administration methods-Target-Controlled Infusion (TCI) and manual infusion-in patients undergoing cerebrovascular bypass surgery.
Summary: This single-center, prospective, family-based observational cohort study aims to investigate susceptibility to moyamoya disease (MMD) and to develop strategies for early screening in individuals at increased familial risk. The study will enroll three groups: patients with MMD, their first-degree relatives, and healthy controls without a family history of MMD. The rationale for this study is that M...
Published Date: October 01, 2017
Published By: National Institutes of Health